The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
about
sameAs
Ivabradine as adjuvant treatment for chronic heart failureIvabradine as adjuvant treatment for chronic heart failureHeart failure guidelines and prescribing in primary care across EuropeRecent advances in treatment of heart failureChallenges in personalised management of chronic diseases-heart failure as prominent example to advance the care processAddressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of IvabradineQuality markers in cardiology: measures of outcomes and clinical practice--a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular SurgeryInequity of access to ACE inhibitors in Swedish heart failure patients: a register-based studyChanges in the use of cardiovascular medicines in the elderly aged 75 years or older--a population-based Kuopio 75+ studyHeart Rate Reduction With Ivabradine Protects Against Left Ventricular Remodeling by Attenuating Infarct Expansion and Preserving Remote-Zone Contractile Function and Synchrony in a Mouse Model of Reperfused Myocardial InfarctionAutonomic dysfunction in mild cognitive impairment: evidence from power spectral analysis of heart rate variability in a cross-sectional case-control study.Individual patient data meta-analysis of beta-blockers in heart failure: rationale and designInfluence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey.International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey.A systematic review of telemonitoring for the management of heart failure.Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure.Administrative data have high variation in validity for recording heart failureThe cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.Optimized treatment and heart rate reduction in chronic heart failure.[Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry].The value of INnovative ICT guided disease management combined with Telemonitoring in OUtpatient clinics for Chronic Heart failure patients. Design and methodology of the IN TOUCH study: a multicenter randomised trial.Tolvaptan: the evidence for its therapeutic value in acute heart failure syndromeAtenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.Adherence to the European Society of Cardiology (ESC) guidelines for chronic heart failure--a national survey of the cardiologists in Pakistan.Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study.A nurse-led up-titration clinic improves chronic heart failure optimization of beta-adrenergic receptor blocking therapy--a randomized controlled trialPhysicians' knowledge of and compliance with guidelines: an exploratory study in cardiovascular diseases.Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis.Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline.Women with heart failure are at high psychosocial risk: a systematic review of how sex and gender influence heart failure self-care.B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode.Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.Patient Medication Adherence and Physician Prescribing among Congestive Heart Failure Patients of Yemen.Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the korean heart failure registry.Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary diseaseDevelopment and validation of algorithms for heart failure patient care: a Delphi studyNational trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010.Epidemiology and clinical aspects of congestive heart failure.Ethnicity and variation in prognosis for patients newly hospitalised for heart failure: a matched historical cohort study.Cardioselective beta-blockers in patients with asthma and concomitant heart failure or history of myocardial infarction: when do benefits outweigh risks?
P2860
Q24185982-3FC4EA23-95A4-4F1B-BD93-BB8EDC596A35Q24201614-6181C19B-9C6E-4F9E-B26E-A4C626956FB3Q24816665-262C960B-9179-4A0D-B88E-6739A3E47258Q26766223-26B75155-40D4-467D-8E8A-EF8E3381317CQ26766461-7E44997D-EB30-4D03-9FB1-1947DC56C755Q26773370-7A8FA18A-782F-443A-98FA-D23F9E6FBD7EQ26778567-8D1BA216-ECFE-47B8-AE67-A5C24B626507Q26799578-B980F823-0563-429F-BB12-6A05A79CE465Q28210079-CF2CA50F-5D22-4581-95A2-F5BE3A50C7E7Q30276924-DB1BDFF8-6580-416F-B470-D07DBD621768Q30438683-88CB1D20-65FB-473A-A29C-0BB7CD7D894DQ30534526-1A9084B1-E2B0-4560-9C26-A49522526822Q30990824-AE635C78-E102-4AC8-A0DD-2D77798FAEAAQ31064781-51D17A8A-5A73-4827-8AB7-49FA654090B9Q33194802-57156A3C-DEDC-4B73-A1F5-918CDDC2C60CQ33400219-638DE44D-3557-4711-97FC-E88383E2BD05Q33712805-9FBF1018-10DC-4802-B4E1-929E15705D62Q33834583-7D7A7054-C17C-402A-A050-68D34151B9AFQ33843442-C20471FB-7594-4F7E-B627-B18F55AE457AQ33912546-94FB7870-6353-4B74-B3B8-6DAA155D0DFEQ33959882-E50505A5-A1E5-4E8C-982D-0DB77F8D3F0BQ33973976-626CA29C-61F7-48C6-B0B6-9CEA1F60ED52Q34051055-6A6CE459-705E-4E64-8B8C-469A9B5E787BQ34076821-3986A085-F27C-4100-8856-A93710E0B4B4Q34170504-CF455EDC-EA78-4039-9F03-F9829E762E27Q34278582-0BC63842-F13A-4958-AAAB-80DAAFA2A805Q34565790-33B80ED8-89CA-473F-B4EA-2DA43B1E5395Q34567802-5DA8E63D-F520-4061-ACAF-19B8A6896B28Q34607730-DDD08E1E-FB93-4CD6-8DDF-D634BDA82F15Q34635764-1541F37D-E4B0-4CAA-BEB6-A5C4D0051855Q35000296-D37D9A4A-8C13-4EB8-98FE-C542A4E7AD3CQ35006600-98BABAB6-1B4B-46E7-93F6-0EA8962DA1EFQ35084777-BEC0AF75-C962-41D1-9488-A4EAB9FE6329Q35154442-6F4C49CF-7301-469A-8751-B3F422840415Q35168749-44864B18-2C6B-4FE8-8A3D-3EFA6A8D6C43Q35555345-FBA04198-90CE-4A95-AEF0-6658D9AEE462Q35556751-7E696201-39CD-4F92-82FE-386A17960875Q35580122-CC5A2F4D-BD55-41A3-9AEE-3E556ED58B0EQ35585101-E6D785DC-6B0C-45F9-8CED-F5BABF8283E1Q35634953-1E441E91-3513-4DC7-A274-E0D0649179E2
P2860
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@ast
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@en
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@nl
type
label
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@ast
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@en
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@nl
prefLabel
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@ast
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@en
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@nl
P2093
P50
P921
P3181
P1476
The EuroHeart Failure Survey p ...... e in Europe. Part 2: treatment
@en
P2093
A Cohen-Solal
J C Aguilar
J Eastaugh
J Korewicki
J Widimsky
Study Group on Diagnosis of th ...... European Society of Cardiology
P304
P3181
P356
10.1016/S0195-668X(02)00700-5
P407
P50
P577
2003-03-01T00:00:00Z